- Guide to PHARMACOLOGY
Synonyms: BMS-986165 | BMS986165 | compound 11 [PMID: 31318208} | Sotyktu® | Tyk2-IN-4
deucravacitinib is an approved drug (FDA (2022))
Compound class: Synthetic organic
Comment: Deucravacitinib (BMS-986165) is a selective, orally active, allosteric inhibitor of the Janus kinase family enzyme, tyrosine kinase 2 (TYK2) [2,5]. The deuteromethyl amide group confers selectivity by virtue of binding to a pocket in the TYK2 JH2 pseudokinase domain.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|Deucravacitinib (BMS-986165) was advanced to evaluation in clinical studies in patients with systemic lupus erythematosus and ulcerative colitis (both Phase 2) and moderate-to-severe psoriasis (Phase 3) . Click here to link to ClinicalTrials.gov's full list of BMS-986165 studies.
Deucravacitinib was granted full FDA approval in September 2022, as a treatment for moderate-to-severe plaque psoriasis (in adults).
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT02534636||Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis||Phase 1 Interventional||Bristol-Myers Squibb|
|NCT03624127||Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis||Phase 3 Interventional||Bristol-Myers Squibb||The POETYK PSO-1 study: deucravacitinib vs. placebo or active comparator apremilast [...].|
|NCT03611751||An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis||Phase 3 Interventional||Bristol-Myers Squibb||The POETYK PSO-2 study [...].|
|NCT04036435||Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis||Phase 3 Interventional||Bristol-Myers Squibb||A deucravacitinib long-term extension trial (POETYK PSO-LTE) in patients from POETYK PSO-1 and 2.|